Toronto, Ontario — August 5, 2025 — Leads & Copy — Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) will present at the OTCQB Venture Virtual Investor Conference on August 7, 2025, in a live, interactive online event. Investors are invited to ask questions in real-time.
Guido Baechler, Executive Chairman of the Board, will represent Telo Genomics and discuss the company’s new strategy for accelerating the development and commercialization of the multiple myeloma MRD and smoldering myeloma assay applications.
The presentation is scheduled for Thursday, August 7th, from 1:00 pm – 1:30 pm ET. Investors can register via the provided link, and an archived webcast will be available after the event. Virtual Investor Conferences (VIC) hosts the event.
Telo Genomics is a biotech company pioneering a telomere platform with applications and prognostic solutions, including liquid biopsies in oncology and neurological diseases. The company combines expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to develop products for pathologists, clinicians, researchers, and drug developers. Telo’s lead application, Telo-MM, is being developed for the treatment of Multiple Myeloma.
For further information, please contact: Guido Baechler, Executive Chairman, 647-477-9365, info@telodx.com
